Everolimus inhibits the progression of ductal carcinoma in situ to invasive breast cancer via downregulation of MMP9 expression.

Conclusions: Targeting mTORC1 can inhibit DCIS progression to IDC via MMP9 and may be a potential strategy for DCIS or Early-Stage IDC therapy.
PMID: 31871301 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - December 22, 2019 Category: Cancer & Oncology Authors: Chen G, Ding X, Pressley K, Bouamar H, Wang B, Zheng G, Broome L, Nazarullah A, Brenner AJ, Kaklamani V, Jatoi I, Sun L Tags: Clin Cancer Res Source Type: research